All Round Doctors, a South Korean startup specializing in digital medical devices, has secured 7 billion KRW(5.4 Million USD) in Series A funding. This investment round was led by existing investor Aon Investment, with participation from UTC Investment, FuturePlay, Korea Investment Partners, and KB Investment. 

All Round Doctors is the only digital healthcare startup in Asia developing medical devices specifically for cancer patients. They plan to conduct clinical trials of ‘CANMORE,’ a device designed to improve chemotherapy adherence and enhance the quality of life for breast cancer patients during treatment, later this year.

All Round Doctors has already commercialized ‘CANMORE PRO,’ a software for monitoring chemotherapy side effects, based on CANMORE. In May, they received approval from global pharmaceutical companies Daiichi-Sankyo and AstraZeneca to provide services to ten major university hospitals, including Yonsei Cancer Center, for the clinical trials of the blockbuster immune-oncology drug Enhertu.

Additionally, to develop technology for integrating and calibrating cancer patients’ side effects with data from wearable devices (RWD), they utilized Samsung Health Stack, an open-source project led by Samsung Electronics to support digital healthcare R&D. This project was showcased as a case study at the annual Samsung Developer Conference in the United States.

With this investment, All Round Doctors will focus on enhancing the medical safety and technological sophistication of CANMORE, aiming to conduct IRB clinical trials with the Ministry of Food and Drug Safety within this year. They also plan to prepare for a comprehensive entry into the Japanese market through collaboration with Japan’s largest CRO (Contract Research Organization) firm.

Lee Jong-Hyun, CEO of Aon Investment, commented, “All Round Doctors is a rapidly growing team formed by internal medicine specialists and IT developers. We anticipate positive clinical outcomes not only from the development of digital medical devices aimed at improving medication adherence in breast cancer patients but also from their ongoing R&D and exploratory clinical trials of ‘survivor-centered personalized healthcare technology’ in collaboration with the National Cancer Center and regional cancer centers.”

Kwak Seong-Dong, CEO of All Round Doctors, stated, “Currently, the field of managing chemotherapy side effects for cancer patients in Korea lacks medical insurance coverage, causing inconvenience for both patients and doctors. Self-monitoring and management are becoming standardized, with guidelines for patient-reported outcomes being presented at major European oncology conferences such as ESMO (European Society for Medical Oncology), and medical insurance coverage is actively being discussed. Through this investment, we aim to achieve medical safety and technological advancements for CANMORE in collaboration with domestic oncology medical professionals.”